All News

The FDA PDUFA date for taparinof cream 1% will be during the 4th quarter, Dermavant said, with approval based on ADORING phase 3 clinical trial data.

Hepatologist Naim Alkhouri, MD, offered 3 take-home thoughts for primary care colleagues to help increase early detection of MASLD.

In STRIDE 10, V116 was superior to PPSV23 in adults aged ≥50 years and naive to pneumococcal vaccine for 8 of 9 serotypes unique to Merck's investigational shot.

Naim Alkhouri, MD, a transplant hepatologist and a resmetirom investigator, talks here about the life-changing impact the drug will have for all touched by MASH.

Primary care is where early detection and treatment of liver disease should begin and as Dr Alkhouri highlights here, all the right tools are already at hand.

The national study on the true prevalence of metabolic dysfunction-associated liver disease is essential to screening, prevention, and treatment efforts, says AFL CEO Stiehl.

Adults receiving semaglutide for the first time achieved weight loss of 14.3% at 12 months vs 10.6% among those who had previously taken a different antiobesity drug.

Your daily dose of the clinical news you may have missed.

Pivmecillinam is an aminopenicillin, a class of beta-lactam antibiotics with a mechanism of action that may help reduce rising levels of antibiotic resistance.

Poor cardiovascular health at midlife was associated with a decline in the mental processing speed of Black women, but not White women, according to a new study.

Your daily dose of the clinical news you may have missed.

Alkhouri, a veteran investigator in the field of hepatic disease, including MASLD and MASH, stresses the need for early detection of MASLD when simple intervention can be effective.

To cover a medical bill, more than half of those surveyed would downsize a home, 75% would take on a second job; more than 1/3 had already skipped care due to costs.

Patients with AF aged younger than 65 years have substantial comorbidity burden that may impact their future risk of mortality, reported researchers.

Your daily dose of the clinical news you may have missed.

Treatment by female physicians resulted in better 30-day outcomes for male and female patients, but the benefit was significantly greater for the women.

Increased arterial stiffness and elevated central BP are among factors researchers found to have strong discriminatory value for PE at term and postpartum.

Researchers found that the COVID-19 booster dose elicited a 71%-84% increase in the median anti-spike half-life over that of the primary series.